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Abstract
Background: Dyspepsia is defined as a chronic or recurrent pain or discomfort centered in the upper abdomen. Endos-
copy is the best strategy for confirming the cause of  dyspepsia. Non- invasive strategies would be more appropriate in low 
resource countries where endoscopy is not readily available. However, there is concern that these strategies may miss seri-
ous disease like gastric cancer. One test that needs to be assessed in this regard is the Helicobacter pylori stool antigen test 
(HPSAT).
Objective: To determine the validity of  the stool antigen test in predicting H. pylori associated disease among patients with 
dyspepsia.
Methods: In this prospective study patients with dyspepsia attending Mulago Hospital were recruited consecutively. Helico-
bacter pylori was determined using the Rapid Strip HpSA ®, endoscopy and gastric mucosal biopsy were done.
Results:   167 patients with dyspepsia were recruited into the study. There were ninety six (57.5%) females and seventy one 
(42.5%) males with an average age of  48.1(±18.1) years. Patients presenting with dyspepsia in Mulago hospital were more 
likely to come from the Central  60  (36%)  and western  tribes  55  (33%).  The  commonest  endoscopic  finding  was 
oesophagitis  25 (15%). Peptic ulcer disease was found in 32 (19.2%) and 54 (32.3%) had normal endoscopy findings. H 
pylori was found in 33.5% and 32.5% using the HPSAT and histology respectively. The validity of  the HPSAT in predicting 
H.pylori associated diseases was generally low with an overall sensitivity of  55.8%, and specificity of  74.2%. However, the 
validity was higher in predicting the diagnosis of  peptic ulcer disease with a sensitivity 59.4% and specificity 72.6%.
Conclusion and recommendations: The HPSAT may be used in the test and treat strategy for young patients with dyspep-
sia without alarm signs and symptoms in low resource settings. However, because of  its low validity in predicting H.pylori 
associated disease, it is important to follow up patients so that if  symptoms persist or recur endoscopy is performed 
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Introduction
Dyspepsia is defined as a chronic or recurrent pain or 
discomfort centered in the upper abdomen1. Helico-
bacter pylori associated diseases such as peptic ulcer 
disease, gastritis and gastric cancer commonly present 
as dyspepsia. In the evaluation of  dyspepsia, clinical 
signs and symptoms have a limited role because they do 
not reliably predict underlying pathology and endosco-
py findings2. Symptom assessment by medical workers 
is therefore not sufficient in the evaluation of  the cause 
of  dyspepsia.
Endoscopy is the best strategy for confirming the cause 
of  dyspepsia. However, it is an expensive procedure 
and is not readily available in low resource countries. 
One of  the main reasons for performing endoscopy in 
patients with dyspepsia is to detect underlying H.pylori 
associated diseases like peptic ulcer.
Non-invasive testing of  H. pylori using the urea breath 
test has been shown to be a useful surrogate marker of  
peptic ulcer disease in patients with dyspepsia in a study 
conducted in the United Kingdom3.
The Helicobacter pylori stool antigen (HPSAT) test has 
been shown to be another accurate non-invasive test 
for the initial diagnosis of  H.pylori infection4. However, 
there is no data on its utility in managing dyspepsia in 
low resource countries. It is in light of  the above that 
we conducted this study.
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Methods
This  was  a  descriptive  cross  sectional  study  con-
ducted  among  patients  with  dyspepsia presenting 
to the  gastroenterology  division  of  Mulago  hospital 
between  October  2009  to April 2010. All patients 
with dyspepsia 12 years and above who had provided 
consent to participate in the study were consecutively 
enrolled into the study. The patients had to have been 
off  proton  pump inhibitor  therapy and antibiotics  for 
atleast 2 weeks.  We excluded patients with dyspepsia 
attributable to non- steroidal ant-inflammatory drugs, 
dysphagia and those with epigastric pain due to pancre-
atic or hepatic disease.
A physical examination was conducted and a question-
naire was administered to obtain social demographics, 
severity of  dyspepsia symptoms, alarm signs and symp-
toms. The study participants  were asked to provide  a 
stool sample  for H.pylori  testing  on the morning of  
endoscopy was performed. The stool was tested imme-
diately using the Rapid Strip HpSA ® from Meridian 
bioscience Europe.
On the day endoscopy  was scheduled,  the procedure 
was done according  to the standard protocol.  At en-
doscopy  a description  of  the findings  was done and 
three gastric mucosal biopsies for histology were taken 
off.
All the data was coded and entered using EpiData com-
puter  software version 3.1, before being transferred to 
stata version 10 for analysis. Approval for the study was 
granted by the School  of   Medicine  Research  and 
Ethics  committee  of   Makerere  University  College 
of  Health sciences
Results
One hundred and ninety seven (197) patients who at-
tended the Gastroenterology division of  Mulago hospi-
tal were screened for eligibility.  One hundred and sixty 
seven (167) patients with dyspepsia were recruited into 
the study (Figure 1). One hundred and sixty patients 
had gastric mucosal biopsy done.
There were ninety six (57.5%) females and seventy one 
(42.5%) males. The average age of  the participants was 
The commonest H.pylori associated endoscopic di-
agnoses in order of  frequency were gastric ulcer 18 
(10.8%),  duodenal  ulcer 17  (10.2%),  cancer  of  
the  stomach  12  (7.2%),  and duodenitis 9 (5.4%). 
 
Figure 1: Patient flow chart
Screened 197 patients
5 patients could not tolerate 
endoscopy
167 enrolled, Stool antigen 
testing and Upper GI 
endoscopy done
2 Endoscopy terminated early 
due to patient discomfort
160 Had gastric mucosal biopsy 
done for histology
25 patients did not return for
endoscopy
5 Biopsy was not done
48.1(±18.1) years with a range of  13 to 84 years 
(Table1).
Oesophagitis  was the commonest non-H.pylori associ-
ated endoscopic diagnosis, found in 25 (15%). Normal 
endoscopy was found in a significant proportion of  pa-
tients 54 (32.3%) (Table 2).
Table 1: socio-demographic characteristics 
 






> 45                                                                   89                                   
46.7 
 







Female                                                              96                                   
57.5 
 






Central                                                             60                                     
36 
 
Western                                                             55                                     
33 
 
Northern                                                            25                                     
15 
 
Eastern                                                              14                                      
8 
 
Non-Ugandans                                                  13                                      
8 
Table 2: Endoscopic and histologic diagnoses among patients with 
dyspepsia 





Normal 54 32.3 
Gastric ulcer 18 10.8 
Duodenal ulcer 17 10.2 
Cancer of the stomach 12 7.2 



















Histologic gastritis 119 71.3 
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The majority of  the patients with cancer of  the stom-
ach 9 (75%) were above 45 years and had alarm features 
(Table 3).
The prevalence of  Helicobacter pylori was 33.5% and 
32.5 % as determined by the HPSAT and histology  re-
spectively.  Among  patients  with H.pylori  associated 
diseases,  the highest prevalence of  H.pylori was found 
among patients with duodenal ulcer using the HPSAT. 
It was found in 10 (58.8%) of  these patients duodenal 
ulcers. It was followed by gastric ulcer 55.6% and gas-
tric cancer 50%.  Among the patients with a normal 
endoscopic diagnosis, the prevalence of  H.pylori using 
the HPSAT was low at 24.1% (table 4). 
The overall sensitivity of  the stool antigen test in pre-
dicting H.pylori associated disease among patients with 
dyspepsia is 55.8%, specificity is 74.2% while the posi-
tive and negative predictive values are 42.9% and 82.9% 
respectively.  It was higher in predicting duodenal ulcer 
Table 3: Characteristics of  patients with Cancer of  the Stomach
Variable                                                               Number (n=12)                        Percentage
Age
Below 45 years                                                          3                                                25
Above 45 years                                                          9                                                75
Alarm features
with a sensitivity and specificity of  58.8% and 69.3% 
respectively followed by gastric ulcer with sensitivity of  
55.6% and sensitivity of  69.1% (table 4).  The test over-
all showed a high negative predictive value for all the 
H.pylori associated diseases.
Other endoscopic findings include: Gastric Polyps 
1(0.6%), gastric Kaposis sarcoma 1(0.6%), gastric
outlet obstruction 5 (3%), portal hypertensive gastropa-
thy1 (0.6%), duodenal mass 2 (1.2%), extrinsic duodenal 
Mass 1 (0.6%), Barrett’s oesophagus  1 (0.6%), dilated 
oesophagus  2 (1.2%), oesophageal ulcers 3 (1.8%), Ca 
oesophagus 1 (0.6%), hiatus hernia 3(1.8%). Table 5 
Table 5: Utility of the HPSAT in predicting Helicobacter pylori 
associated diseases among patients with dyspepsia 
 












disease Sensitivity (%) 55.6 55.8 50 55.8 
Specificity (%) 69.1 69.3 67.7 74.2 
Positive predictive 
value (%) 
17.9 18 10.7 42.9 
Negative predictive 
value (%) 
92.8 93.7 94.6 82.9 
 
Discussion
In this study, oesophagitis 25 (15%) was the common-
est endoscopic diagnosis. Gastric ulcer was found in18 
(10.8%) and duodenal ulcer in 17 (10.2%).   These find-
ings are similar to earlier studies in Mulago hospital5. 
Other studies from Africa have reported higher rates 
of  duodenal  ulcer6. In both these studies the preva-
lence  of  H. pylori was above  70%. It is possible that 
the high prevalence of  H.pylori was responsible for the 
observed differences in the frequency of  peptic ulcer 
disease. Gastric cancer was found in 12(7.2%) which 
is similar to findings from other African studies 5 7 8. 
A large proportion of  the patients with gastric cancer 
were from the western tribes 6 (50%). In addition the 
majority of  these patients with cancer of  the stomach 
were over 45 years of  age and had alarm features (Table 
3). Ibingira had  similar results in 2001 where he found 
49% of  the patients were from south western Uganda. 
The mean age of  his patients was 53.8 years for females 
and 56.1 for males9.
The overall  prevalence  of  Helicobacter  pylori among 
patients  with dyspepsia  at Mulago hospital was 33.5% 
as determined by the H.pylori stool antigen test while it 
was 32.5% as determined  by  histology.  It  is  possible 
therefore  that  the  prevalence  of   active  H.pylori in-
fection is much lower than the sero-prevalence. In our 
study patients were required to have been off  proton 
pump inhibitor and antibiotics for atleast two weeks. 
However, most of  our patients 146 (73%) reported 
symptoms lasting over 4 weeks and during that period 
63 (38.9%) had been prescribed atleast one of  the an-
tibiotics used for H.pylori treatment. It is possible that 
some of  these patients could have eradicated the organ-
ism before testing had been done, leading to a lower 
prevalence rate. In Ghana and Nigeria prevalence rates 
of  75.4%, 73% and 81%, have been reported using his-
tology and CLO urease tests 7 10 11. It is possible that the 
prevalence of  active infection has declined in Uganda 
while that in Ghana and Nigeria has remained constant. 
Other studies may therefore be needed to determine 
the prevalence  of  active H.pylori infection in Uganda 
and if  there have been any changes in the pattern over 
the years. In developed countries the prevalence of  
H.pylori has been noticed to be decreasing 12.
The  HPSAT  had a higher  validity  in predicting  di-
agnosis  of   peptic  ulcer  disease  with a sensitivity of  
59.4% and specificity of  72.6% and in predicting the 
diagnosis of  cancer of  the stomach with a sensitivity 
of  50% and specificity of  67.7%. With this overall low 
sensitivity the HPSAT may still be used in the test and 
treat strategy especially in low resource settings, among 
young patients less than 45 years of  age with no alarm 
symptoms. In this age group even  if   the  test  missed  to 
predict  some  cases  of   H.pylori  associated  diseases, 
these  are relatively few and most of  them are benign. 
In any case, using this strategy,  the H.pylori negative 
patients would be treated with a PPI(proton pump in-
hibitor) which may result in improvement in the benign 
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Table4:  Endo scopic diagnoses and prevalence Helicobacter pylori 
 
Helicobacter pylori HPSAT 
 
                                                   Positive                                    Negative 
 





Gastric ulcer                           10 (55.6%)                               8 (44.4%) 
Gastric cancer                          6 (50%)                                     6 (50%) 
Duodenal ulcer                              10 (58.8%)                                3 (33.3%) 
Duodenitis                                    7 (41.2%)                                  6(66.7%)     
H.pylori associated diseases. However, it is important to 
follow up patients when this strategy is used,  so that if  
symptoms  persist,  endoscopy  is done  to confirm  the 
diagnosis  of  any H.pylori associated disease that may 
have been missed by a negative HPSAT.
Conclusions
The helicobacter pylori stool antigen test may have a 
role in the non-invasive management of  dyspepsia  in 
low  resource  setting.  In  our  study  most  of   the 
patients  with  cancer  of   the stomach were above 45 
years and all had alarm features.
We recommend the use of  the HPSAT in the non-inva-
sive management of  dyspepsia in low resource settings 
only for young people less than 45 years old without 
alarm signs and symptoms.  However,  because  of   its 
low  validity  in  predicting  H.pylori  associated  disease, 
it  is important to follow up patients so that if  symp-
toms persist or recur endoscopy is performed.
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